

## LIST OF PUBLICATIONS (JÓZSEF TŐZSÉR)

2009. feb. 28

1. Farkas E., Tőzsér J. és Gergely A. (1986). Vizsgálatok az átmenetifém-peptid komplexek körében, XI. Az L-szeril-glicin komplexképző sajátságai. *Magy. Kém. Folyóirat*, 92, 49-54. (IF1986 = 0.443)
2. Tőzsér, J., Cs-Szabó, G., Pozsgay, M., Aurell, L. and Elődi, P. (1986) Active centre studies on bovine pancreatic chymotrypsin with tripeptidyl-p-nitroanilide substrates. *Acta Biochim. Biophys. Hung.* 21, 335-348. (IF1986 = 0.875)
3. Cs-Szabó, G., Tőzsér, J., Aurell, L. and Elődi, P. (1986). Mapping of the substrate binding site of human leukocyte chymotrypsin (cathepsin G) using tripeptidyl-p-nitroanilide substrates. *Acta Biochim. Biophys. Hung.* 21, 349-362. (IF1986 = 0.875)
4. Tőzsér, J. (1986). A pankreász és leukocita kimotripszin vizsgálata szintetikus szubsztrátokkal. *Biokémia*, 10, 75-78.
5. Punyiczki, M., Berta, A. and Tőzsér, J. (1988) Study of neutral proteinases of human tears using gels containing copolymerized substrates. *Clin. Chem. Enzyme Comms.* 1, 115-124.
6. Tőzsér, J., Berta, A. and Punyiczki, M. (1989) Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. *Clin. Chim. Acta* 183, 323-331. (IF1989 = 1.273)
7. Tőzsér, J., Hamvas, A., Rády, P., Kertai, P. and Elődi, P. (1989). Plasminogen activator and plasmin-like activities in experimental rat tumours. *Acta Biochim. Biophys. Hung.* 24, 119-128. (IF1989 = 0.508)
8. Berta, A., Vámosi, P. and Tőzsér, J. (1989) Eine neue Methode zur semiquantitativen Alpha-1 Antitrypsinbestimmung in der menschlichen Tänenflussigkeit. *Fortschr. Ophthalmol.* 86, 773-776.
9. Tőzsér, J., Hamvas, A., Rády, P., Kertai, P. és Elődi, P. (1990). Plazminogén aktivátor és plazminszerű aktivitás patkányok kísérletes tumoraiban. *Kísérletes Orvostudomány*, 42, 1-5.
10. Tőzsér, J. and Berta, A. (1990) Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears. *Exp. Eye Res.* 51, 33-37. (IF1990 = 1.777)
11. Copeland, T.D., Wondrak, E.M., Tőzsér, J., Roberts, M. and Oroszlan, S. (1990) Substitution of proline with pipercolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. *Biochem. Biophys. Res. Commun.* 169, 310-314. (IF1990 = 3.606)
12. Berta, A., Tőzsér, J., and Holly, F.J. (1990) Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. *Acta Ophthalmol. (Copenh)*. 68, 508-514. (IF1990 = 0.417)
13. Tőzsér, J., Marsalkó, T.M., Punyiczki, M. and Elődi, P. (1990) The enzyme capable to cleave trypsin active site titrant as substrate is a carboxylesterase with electrophoretic mobility similar to albumin. *Acta Biophys. Biophys. Hung.* 25, 57-65. (IF1990 = 0.373)
14. Oroszlan, S. and Tőzsér, J. (1990) The retroviral proteinases. *Seminars Virol.* 1, 369-378.
15. Tőzsér, J., Gustchina, A., Weber, I.T., Bláha, I., Wondrak, E.M. and Oroszlan, S. (1991) Studies on the role of the S<sub>4</sub> substrate binding site of HIV proteinases. *FEBS Lett.* 279, 356-360. (IF1991 = 3.479)

16. Tózsér, J., Bláha, I., Copeland, T.D., Wondrak, E.M. and Oroszlan, S. (1991) Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. *FEBS Lett.* 281, 77-80. (IF 1991 = 3.479)
17. Tózsér, J. and Berta, A. (1991) Plasminogen activator inhibitors in human tears. *Acta Ophthalmol. (Copenh.)* 69, 426-431. (IF1991 = 0.543)
18. Berta, A., Holly, F.J., Tózsér, J. and Holly, T.F. (1991) Tear plasminogen activators - indicators of epithelial cell destruction. The effect of scraping, n-heptanol debridement and alkali burn of the cornea on the plasminogen activator activity of rabbit tears. *Int. Ophthalmol.* 15, 363-369. (IF1991 = 0.550).
19. Bláha, I., Nemeč, J., Tózsér, J. and Oroszlan, S. (1991) Synthesis of homologous peptides using fragment condensation: Analogs of a HIV proteinase substrate. *Int. J. Pept. Prot. Res.* 38, 453-458. (IF1991 = 1.587).
20. Tózsér, J., Weber, I.T., Gustchina, A., Bláha, I., Copeland, T.D., Louis, J.M. and Oroszlan, S. (1992) Kinetic and modeling studies of S<sub>3</sub>-S<sub>3</sub>' subsites of HIV proteinases. *Biochemistry*, 31, 4794-4800. (IF1992 = 5.196)
21. Punyiczki, M., Berta, A. and Tózsér, J. (1992) Determination of collagenolytic activity in human tears by microtiter method. *Clin. Chem. Enzyme Comms.* 4, 429-437.
22. Bláha, I., Tózsér, J., Copeland, T.D. and Oroszlan, S. (1992) Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of chemically synthesized HIV-2 proteinase. *FEBS Lett.* 309, 389-393. (IF1992=3.505).
23. Tózsér, J. és Oroszlan, S. (1992) A HIV proteinázok specifitása. *Biokémia* 14, 169-174.
24. Tózsér, J., Friedman, D., Weber, I.T., Bláha, I. and Oroszlan, S. (1993) Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. *Biochemistry*, 32, 3347-3353. (IF1993 = 5.109).
25. Weber, I.T., Tózsér, J., Wu, J., Friedman, D. and Oroszlan, S. (1993) Molecular model of the equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. *Biochemistry*, 32, 3354-3362. (IF1993 = 5.109).
26. Oroszlan, S., Tózsér, J., and Weber, I.T. (1993) The proteinases of bovine leukemia and equine infectious anemia viruses. *Int. Antiviral News*, 1, 22-23.
27. Tózsér, J., Bagossi, P., Weber, I.T., Copeland, T.D. and Oroszlan, S. (1996) Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. *J. Biol. Chem.* 271, 6781-6788. (IF1996 = 7.452)
28. Nógrády, N., Pócsi, I., Katona, É., Jeney, V., Boross, P., Tózsér, J., Fachel, J. and Szentirmai, A. (1996) Intracellular and extracellular cyclodextrin glycosyltransferases of *Bacillus macerans* show identical enzymological characteristics and antigenicity. *J. Basic Microbiol.* 36, 335-340 (IF1996 = 0.490)
29. Bagossi, P., Cheng, Y.-S.E., Oroszlan, S. and Tózsér, J. (1996) Activity of linked HIV-1 proteinase dimers containing mutations in the active site region. *Protein Eng.* 9, 997-1003 (IF1996 = 1.975)
30. Pitlik J., Bagossi, P., Jeko, J. and Tózsér, J. (1996) Synthesis of cephalosporin oligopeptides as potential proteinase inhibitors. *Pharmazie*, 51, 700-704. (IF1996 = 0.487)
31. Bogáti, M.Sz., Pócsi, I., Maticsek, J., Boross, P., Tózsér, J. and Szentirmai, A. (1996) NADP-specific glutamate dehydrogenase of *Penicillium chrysogenum* has a homohexamer structure. *J. Basic Microbiol.* 36, 371-375. (IF1996 = 0.490)

32. Briggs, C.J., Tözsér, J. and Oroszlan, S. (1996) Effect of cyclosporin A on the replication cycle of human immunodeficiency virus type 1 derived from H9 and Molt-4 producer cells. *J. Gen. Virol.* 77, 2963-2967 (IF1996 = 3.080)
33. Tözsér, J., Yin, F.H., Cheng, Y.-S.E., Bagossi, P., Weber, I.T., Harrison, R.W. and Oroszlan, S. (1997) Activity of tethered human immunodeficiency virus 1 proteinase containing mutations in the flap region of one subunit. *Eur. J. Biochem.* 244, 235-241 (IF1997 = 3.136)
34. Tözsér, J., Bagossi, P., Weber, I.T., Louis, J.M., Copeland, T.D. and Oroszlan, S. (1997) Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. *J. Biol. Chem.* 272, 16807-16814 (IF1997 = 6.963).
35. Tözsér, J. (1997) Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage. *Pathology Oncology Research*, 3, 141-146.
36. Takács L., Boross, P., Tözsér, J., Módis, L. Jr., Tóth, G. and Berta A. (1998) Transforming growth factor- $\beta$  induced protein,  $\beta$ IG-H3 is present in degraded form and altered localization in lattice corneal dystrophy type I. *Exp. Eye Res.* 66, 739-745 (IF1998 = 2.103).
37. Bagossi P., Cheng, Y.-S.E., Oroszlan, S. and Tözsér J. (1998) Comparison of the specificity of homo- and heterodimeric HIV-1 and HIV-2 proteinase dimers. *Protein Eng.* 11, 439-445. (IF1998 = 2.947)
38. Louis, J.M., Oroszlan, S and Tözsér, J. (1999) Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. *J. Biol. Chem.* 274, 6660-6666 (IF1999 = 7.666)
39. Boross, P., Bagossi, P., Copeland, T.D., Oroszlan, S., Louis, J.M. and Tözsér, J. (1999) Effect of substrate residues on the P2' preference of retroviral proteinases. *Eur. J. Biochem.* 264, 921-929 (IF1999 = 3.307)
40. Tözsér, J., Bagossi, P., Boross, P., Louis, J.M., Oroszlan, S., Majerova, E. and Copeland, T.D. (1999) Effect of serine and tyrosine phosphorylation on retroviral cleavage site substrates. *Eur. J. Biochem.* 265, 423-429 (IF1999 = 3.307)
41. Briggs, C., Ott, D.E., Coren, L.V., Oroszlan, S. and Tözsér, J. (1999) Comparison of the effect of FK506 and cyclosporin A on virus production of H9 cells chronically and newly infected with HIV-1. *Arch. Virology* 144: 2151-2160 (IF1991 = 1.591)
42. Skuta, G., Fisher, G.M., Janaky, T., Kele, Z., Szabó, P., Tözsér, J. and Sümegi, B. (1999) Molecular mechanism of the short-term cardiotoxicity caused by 2'3'-siseoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reaction. *Biochem. Pharmacol.* 58, 1915-1925. (IF1999 = 2.755)
43. Fenyőfalvi, Gy., Bagossi, P., Copeland T.D., Oroszlan, S, Boross, P. and Tözsér, J. (1999) Expression and characterization of human foamy virus proteinase. *FEBS Lett.* 462, 397-401 (IF1999 = 3.720)
44. Bagossi, P., Zahuczky, G., Tözsér, J., Weber, I.T. and Harrison, R.W. (1999) Improved parameters for generating partial charges: correlation with observed dipole moments. *J. Mol. Modeling* 5, 143-152 (IF1999 = 1.267)
45. Tözsér, J. and Berta, A. (1998) Lactate dehydrogenase activity in pathological human tears obtained with glass capillaries correlates with the albumin content. *Int. Ophthalmol.* 22, 289-292. (IF1998 = 0.302)
46. Zahuczky G., Boross, P., Bagossi, P., Emri, G., Oroszlan, S., Louis, J.M. and Tözsér J. (2000) Cloning of the bovine leukemia virus proteinase in *Echerichia coli* and comparison of its

- specificity to that of human T-cell leukemia virus proteinase. *Biochem. Biophys. Acta*, 1478, 1-8. (IF2000 = 1.399)
47. Louis, J.M., Weber, I.T., Tözsér, J., Clore, G.M. and Gronenborn, A.M., (2000) HIV protease: maturation, enzyme specificity, and drug resistance. *Adv. Pharmacol.* 49, 111-146.
  48. Tözsér, J., Zahuczky G., Bagossi P., Louis, J.M., Copeland, T.D., Oroszlan, S., Harrison, R.W. and Weber, I.T. (2000). Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. *Eur. J. Biochem.* 267, 6287-6295. (IF2000 = 2.852)
  49. Csutak A., Tözsér J., Békési L., Hassan, Z., Berta, A. and Silver, D.M. (2000) Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. *Inv. Ophthalmol. Vis. Sci.* 41, 3743-3747 (IF2000 = 4.373).
  50. Gaspar, R. Jr., Bagossi, P., Bene, L., Matko, J., Szollosi, J., Tozser, J., Fesus, L., Waldmann, T.A. and Damjanovich, S. (2001) Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data. *J. Immunol.* 166, 5078-5086 (IF2001 = 7.065).
  51. Ishima, R., Ghirlando, R., Tözsér, J., Gronenborn, A., Torchia, D.A. and Louis, J.M. (2001) Folded monomer of HIV-1 protease. *J. Biol. Chem.* 276, 49110-49116. (IF2001 = 7.258)
  52. Kapust, R.B., Tözsér, J., Fox, J.D., Anderson, D.E., Cherry, S., Copeland, T.D. and Waugh, D.S. (2001) Tobacco etch virus nuclear inclusion protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. *Protein Eng.* 14, 993-1000. (IF2001 = 2.718)
  53. Tözsér, J. (2001) HIV Inhibitors. Problems and reality. *Ann. N. Y. Acad. Sci.* 946, 145-159. (IF 2001= 1.593)
  54. Mahalingam, B., Boross, P., Wang, Y.F., Louis, J.M., Fischer, C.C., Tözsér, J., Harrison, R.W. and Weber, I.T. (2002) Combining mutations in HIV-1 protease to understand mechanisms of resistance. *Proteins* 48, 107-116 (IF2002 = 4.096)
  55. Kapust, R.B., Tözsér, J., Copeland, T.D. and Waugh, D.S. (2002) The P1' specificity of tobacco etch virus protease. *Biochem. Biophys. Res. Commun.* 294, 949-955. (IF2002 = 2.935)
  56. Fehér, A., Weber, I.T., Bagossi, P., Boross, P., Mahalingam, B., Louis, J.M., Copeland, T.D., Torshin, I.Y., Harrison, R.W., Oroszlan, S. and Tözsér, J. (2002) Effect of sequence polymorphism and drug resistant mutations at two HIV-1 Gag cleavage sites on their proteolytic susceptibility. *Eur. J. Biochem.* 269, 4114-4120. (IF2002 = 2.999)
  57. Csutak, A., Tözsér, J., Hassan, Z., Silver, D.M., Berta, A. (2002) A plazminogén aktivátor aktivitás változásának jelentősége a könnyben fotorefraktív excimer lézerkezelés (PRK) után. *Szemészet* 139, 61-65.
  58. Csutak, A., Tözsér, J., Hassan, Z., Silver, D.M., Berta, A. (2002) Fotorefraktív excimer lézerkezelést (PRK) követő korneális sztómahomályok. *Endoscopia és Minimálisan Invazív Terápia* 5, 19-22.
  59. Tözsér, J., Shulenin, S., Kádas, J., Boross, P., Bagossi, P., Copeland, T.D., Nair, B.C., Sarngadharan, M.G. and Oroszlan, S. (2003) Human immunodeficiency virus type-1 capsid protein is a substrate of retroviral proteinase while integrase is resistant toward proteolysis. *Virology* 310, 16-23. (IF2003 = 3.391)
  60. Tözsér, J., Bagossi, P., Zahuczky, G., Specht, S.I., Majerova, E. and Copeland, T.D. (2003) Effect of caspase cleavage site phosphorylation on proteolysis. *Biochem. J.* 372, 137-143. (IF2003 = 4.101).

61. Tözsér J. (2003) Stages of HIV replication as targets for therapeutic intervention. *Curr. Top. Med. Chem.* 3, 1447-1457.
62. Tözsér, J. and Oroszlan, S. (2003) Proteolytic events of HIV-1 replication as targets for therapeutic intervention. *Curr. Pharm. Des.* 9, 1803-1815 (IF2003 = 5.550).
63. Csutak A, Silver, D.M., Tözsér, J., Facskó, A. and Berta, A. (2003) Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. *Exp. Eye Res.* 77, 675-680. (IF2003 = 2.611).
64. Csutak, A., Silver, D.M., Tözsér J., Hassan, Z. and Berta, A. (2004) Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy and pregnancy as a risk factor. *Inv. Ophthalmol. Vis. Sci.* 45, 1329-1333. (IF2004 = 3.577).
65. Tözsér, J., Shulenin, S., Louis, J.M., Copeland, T.D. and Oroszlan, S. (2004) Processing of wild type and mutant HIV-1 nucleocapsid proteins by the HIV-1 proteinase. *Biochemistry*, 43, 4304-4312. (IF2003=4.008).
66. Mahalingam, B., Wang, I.F., Boross, P., Tözsér, J., Louis, J.M., Harrison, R.W. and Weber, I.T. (2004) Crystal structures of HIV protease V82A and L90M mutants reveal changes in indinavir binding site. *Eur. J. Biochem*, 271, 1516-1524. (IF2003 = 3.260).
67. Fehér, A., Boross, P., Sperka, T., Oroszlan, S. and Tözsér J. (2004) Expression of the murine leukemia virus protease in fusion with maltose binding protein in *Escherichia Coli*. *Protein Expression and Purification.* 35, 62-68 (IF2003 = 1.336).
68. Kádas, J., Weber, I.T., Bagossi, P., Miklóssy, G., Boross, P., and Tözsér, J. (2004) Narrow substrate specificity and sensitivity towards ligand binding site mutations of human T-cell leukemia virus protease. *J. Biol. Chem.* 279, 27148-27157 (IF2003 = 6.355).
69. Bagossi, P., Kádas, J., Miklóssy, G., Boross, P., Weber, I.T. and Tözsér, J. (2004) Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. *J. Virol. Methods*, 119, 87-93 (IF2004 = 1.729).
70. Nallamsetty, S., Kapust, R.B., Tözsér, J., Cherry, S., Tropea, J.E. and Waugh, D.S. (2004) Efficient, site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro. *Protein Expression and Purification.* 38, 108-115. (IF2004 = 1.336).
71. Tözsér, J., Tropea, J.E., Cherri, S., Bagossi, P., Copeland, T.D., Wlodawer, A. and Waugh, D.S. (2005) Comparison of the substrate specificity of two potyvirus proteases. *FEBS J.* 272, 514-523. (IF2005 = 3.164)
72. Bagossi P., Horváth, G., Vereb, G., Szöllösi, J. and Tözsér, J. (2005) Molecular modeling of nearly full length ErbB2 receptor. *Biophys. J.* 88, 1354-1363. (IF2005 = 4.507).
73. Bagossi, P., Sperka, T., Fehér, A., Kádas, J., Zahuczky, G., Miklóssy, G., Boross, P. and Tözsér, J. (2005) Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. *J. Virol.* 79, 4213-4218. (IF2005 = 5.178).
74. Sperka, T., Pitlik, J., Bagossi, P. and Tözsér, J. (2005) Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. *Bioorg. Med. Chem. Letters* 15, 3086-3090. (IF2005 = 2.478).
75. Tie, Y., Boross, P., Wang, Y.F., Gaddis, L., Liu, F., Chen, X., Tözsér, J., Harrison, R.W. and Weber, I.T. (2005) Molecular basis for substrate recognition and drug resistance from 1.1-1.6 Å resolution crystal structures of HIV-1 protease mutants with substrate analogs. *FEBS J.* 272, 5265-5277. (IF 2005 = 3.164)
76. Liu, F., Boross, P.I., Wang, Y.F., Tözsér, J., Louis, J.M., Harrison, R.W. and Weber, I.T. (2005) Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1

- protease with drug-resistant mutations L24I, I50V, and G73S. *J. Mol. Biol.* 354, 789-800. (IF 2005 = 5.229)
77. Boross, P., Tözsér, J. and Bagossi, P. (2006) Improved purification protocol for wild-type and mutant human foamy virus proteases. *Protein Express. Purif.* 46, 343-347. (IF2006 =1.856).
  78. Mitchell, M.S., Tozser, J., Princler, G., Lloyd, P.A., Ashleigh, A. and Derse, D. (2006) Synthesis, processing and composition of the virion-associated HTLV reverse transcriptase. *J. Biol. Chem.* 281, 3964-3971. (IF 2006 = 5.808)
  79. Tözsér\*, J., Shulenin\*, S., Young, M.R., Briggs, C.J., and Oroszlan, S. (2006) Replication-dependent fitness recovery of Human immunodeficiency virus 1 harbouring mutations of Asn17 of the nucleocapsid protein. *J. Gen. Virol.* 87, 961-965. (IF 2006 = 3.110).
  80. Fehér, A., Boross, P., Sperka, T., Miklóssy, G., Kádas J., Bagossi, P., Oroszlan, S., Weber, I.T. and Tözsér, J. (2006) Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. *J. Gen. Virol.* 87, 1321-1330. (IF 2006 = 3.110).
  81. Sperka, T., Boross, P., Eizert, H., Tözsér, J. and Bagossi, P. (2006) Effect of mutations on the dimer stability and pH optimum of the human foamy virus protease. *Protein Eng. Des. Sel.* 19, 369-375. (IF 2006 = 3.000)
  82. Fang B., Boross, P., Tözsér, J. and Weber, I.T. (2006) Structural and kinetic analysis of caspase-3 reveals role for S5 binding site in substrate recognition. *J. Mol. Biol.* 360, 654-666. (IF 2006 = 4.890)
  83. Tie, Y., Kovalevsky, A.Y., Boross, P., Wang, Y.F., Ghosh, A.K., Tozser, J., Harrison, R.W. and Weber, I.T. (2007) Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. *Proteins.* 67, 232-242 (IF2007 = 3.354).
  84. Tözsér, J. and Weber, I.T. (2007) Human T-cell leukemia virus protease as a potential therapeutic target. *Curr. Pharm. Des.* 13, 1285-1294 (IF 2007 = 4.868)
  85. Varga, A., Bagossi, P., Tözsér, J. Peitl, B. and Szilvassy, Z. (2007) Effect of experimental hypercholesterolaemia on K<sup>+</sup> channel  $\alpha$ -subunit mRNA levels in rabbit hearts. *Eur. J. Pharmacol.* 562(1-2):130-1. (IF 2007 = 2.376).
  86. Sperka, T., Miklóssy, G., Tie, Y., Bagossi, P., Zahuczky, G., Boross, P., Matúz, K., Harrison, R.W., Weber, I.T. and Tözsér, J. (2007) Bovine leukemia virus protease: comparison with human T-cell leukemia virus and human immunodeficiency virus proteases. *J. Gen. Virol.* 88, 2052-2063. (IF 2007 = 3.120)
  87. Olivares, I., Mulky, A., Boross, P.I., Tözsér, J., Kappes, J.C., López-Galíndez, C. and Menéndez-Arias, L. (2007) HIV-1 Protease Dimer Interface Mutations that Improve the Stability of the Viral Reverse Transcriptase in Infectious Virions. *J. Mol. Biol.* 372(2):369-81. (IF2007 = 4.472)
  88. Wang, Y.F., Tie, Y., Boross, P.I., Tözsér, J., Ghosh, A.K., Harrison, R.W. and Weber, I.T. (2007) Potent antiviral GRL-98065 shows similar inhibition and structural interactions with drug resistant mutants and with wild-type HIV-1 protease. *J. Med Chem.* 50, 4509-4515. (IF2007 = 4.895).
  89. Csutak, A., Silver, D.M., Tözsér, L. and Berta, A. (2007) Wound healing and urokinase plasminogen activator after laser vision correction surgery. *J. Hopkins APL Techn. D.* 27(3) 198-207. (IF2007 = 0.132).
  90. Menendez-Arias, L. and Tözsér, J. (2008) HIV-1 protease inhibitors: effects on HIV-2 replication and resistance protease. *Trends in Pharmacological Sciences* 29(1):42-49. (IF2007 = 9.610)

91. Csutak A., Silver, D., Tözsér, J., Steiber, Z., Bagossi, P., Hassan, Z., and Berta, A. (2008) Plasminogen activator inhibitor in human tears after laser refractive surgery. *J. Cataract. Refr. Surg.* 34(6), 897-901 (IF2007 = 2.497).
92. Miklóssy, G., Tözsér, J., Kadas, J., Louis, J.M., Ishima, R. and Bagossi, P. (2008) Novel macromolecular inhibitors of HIV-1 protease. *Protein Eng. Des. Sel.* 21(7):453-61. Epub 2008 May 13. (IF2007 = 2.662).
93. Kádas\* J., Boross\* P., Weber, I.T., Bagossi, P., Matúz K. and Tözsér J. (2008) C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for efficient dimerization and for catalytic activity. *Biochem. J.* 416(3):357-64. 2008 Jul 17. [Epub ahead of print] (IF2007 = 4.009)
94. Eizert, H., Bander, P., Bagossi, P., Sperka, T., Miklóssy, G., Boross, P., Weber, I.T. and Tözsér, J. (2008) Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. *J. Virol.* 82(20):10111-10117. (IF2007 = 5.332).
95. Benko, S., Tozser, J., Miklossy, G., Varga, A., Kadas, J., Csutak, A. , Berta, A. and Rajnavolgyi, E. (2008) Constitutive and UV-B modulated expression of Nod-like receptors and their functional partners in human corneal epithelial cells. *Mol. Vis.* 14, 1575-83. (IF2007 = 2.329).
96. Zhang, D., Tözsér, J. and Waugh, D.S. (2009) Molecular cloning, overproduction, purification and biochemical characterization of the p39 nsp2 protease domains encoded by three alphaviruses. *Protein Expr. Purif.* 64(1):89-97. (IF2007 = 1.940).
97. Boross, P., Bagossi, P., Weber, I.T. and Tözsér, J. (2008) Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection. *Inf. Dis. Drug Targets*, accepted for publication.

Total impact factors of the publications: 263.374

#### BOOK CHAPTERS:

1. Berta, A., Punyiczki, M. and Tözsér, J. (1988) Collagenase in normal and pathological human tears determined by microtiter plate method. In: *Ophthalmology Today* (De Oliveira, L.N.F., ed.), Elsevier Science Publishers, B.V., Amsterdam, pp. 503-506.
2. Berta A., Tözsér J. and Punyiczki M. (1990). The role of the plasminogen activator-plasmin system of human tears in anterior segment pathology. in: *Lacrimal System*. (Miglior M., Spinelli D. and Fabbri G., eds.) Kugler & Ghedini, Amsterdam, pp. 115-120
3. Berta, A., and Tözsér, J. (1991) Plasminogen activator and plasminogen activator inhibitor determinations in the tears of patients with keratoconjunctivitis sicca an Sjörge'n's syndrome. in: *New frontiers in ophthalmology* (Khoo, C.Y. et al., eds), Elsevier Science Publishers, B.V., Amsterdam, pp. 777-779.
4. Berta, A., Tözsér, J. and Holly, F.J. (1991). Multilevel inhibition of proteases in tears. Changing concepts in and practical approach for the protease-inhibitor treatment of corneal ulcers. in: *The Lacrimal System 1990* (van Bijsterveld O.P., Lemp M.A., Spinelli D. eds.) Kugler & Ghedini, Amsterdam, pp. 21-26.
5. Copeland, T.D., Bláha, I., Tözsér, J. and Oroszlan, S. (1991). Totally synthetic retroviral proteins: Proteases and nucleic acid binding proteins. in: *Peptides: Chemistry and Biology*, (Smith, J.A. and Rivier, J.E. eds.) Escom, The Netherlands, pp. 717-718.

6. Tözsér, J., Menéndez-Arias, L. and Oroszlan, S. (1998) Equine infectious anemia virus retropepsin. *in* Handbook of Proteolytic Enzymes, (Barrett, A.J. et al., eds), Academic Press, New York, pp. 932-935
7. Menéndez-Arias, L., Tözsér, J. and Oroszlan, S. (1998) Moloney murine leukemia virus retropepsin *in* Handbook of Proteolytic Enzymes, (Barrett, A.J. et al., eds), Academic Press, New York, pp. 946-949
8. Menéndez-Arias, L., Tözsér, J. and Oroszlan, S. (1998) Mouse mammary tumor virus retropepsin. *in* Handbook of Proteolytic Enzymes, (Barrett, A.J. et al., eds), Academic Press, New York, pp. 944-946.
9. Tözsér, J., Menendez-Arias, L. and Oroszlan, S. (2004) Equine infectious anemia virus retropepsin. *in* Handbook of Proteolytic Enzymes, 2nd ed. (Barrett, A.J., Rowlings, N.D. and Woessner, J.F. eds), Elsevier Science Ltd. London, pp 160-163.
10. Menendez-Arias, L., Tözsér, J. and Oroszlan, S. (2004) Moloney murine leukemia virus retropepsin *in* Handbook of Proteolytic Enzymes, 2nd ed. (Barrett, A.J., Rowlings, N.D. and Woessner, J.F. eds), Elsevier Science Ltd. London, pp 176-178.
11. Menendez-Arias, L., Tözsér, J. and Oroszlan, S. (2004) Mouse mammary tumor virus retropepsin. *in* Handbook of Proteolytic Enzymes, 2nd ed. (Barrett, A.J., Rowlings, N.D. and Woessner, J.F. eds), Elsevier Science Ltd. London, pp 174-176.